Small molecules that directly target MYC and are also well tolerated in vivo will provide invaluable chemical probes and potential anti-cancer therapeutic agents. We developed a series of small-molecule MYC inhibitors that engage MYC inside cells, disrupt MYC/MAX dimers, and impair MYC-driven gene expression. The compounds enhance MYC phosphorylation on threonine-58, consequently increasing proteasome-mediated MYC degradation. The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index. An improved analog, MYCi975 showed better tolerability. These findings suggest the potential of small-molecule MYC inhibitors as chemical probes and possible anti-cancer therapeutic agents.
Summary
Oncogenic mutations in two isocitrate dehydrogenase
(IDH)-encoding genes (IDH1 and
IDH2) have been identified in acute myelogenous leukemia,
low-grade glioma, and secondary glioblastoma (GBM). Our in
silico and wet-bench analyses indicate that non-mutated IDH1 mRNA
and protein are commonly overexpressed in primary GBM. We show that genetic and
pharmacologic inactivation of IDH1 decreases GBM cell growth, promotes a more
differentiated tumor cell state, increases apoptosis in response to targeted
therapies, and prolongs survival of animal subjects bearing patient-derived
xenografts (PDXs). On a molecular level, diminished IDH1 activity results in
reduced α-ketoglutarate (αKG) and NADPH production, paralleled
by deficient carbon flux from glucose or acetate into lipids, exhaustion of
reduced glutathione, increased levels of reactive oxygen species (ROS), and
enhanced histone methylation and differentiation marker expression. These
findings suggest that IDH1 upregulation represents a common metabolic adaptation
by GBM to support macromolecular synthesis, aggressive growth, and therapy
resistance.
SUMMARY
The Super Elongation Complex (SEC) is required for robust and productive transcription through release of RNA Polymerase II (Pol II) with its P-TEFb module and promoting transcriptional processivity with its ELL2 subunit. Malfunction of SEC contributes to multiple human diseases including cancer. Here, we identify peptidomimetic lead compounds, KL-1 and its structural homolog KL-2, which disrupt the interaction between the SEC scaffolding protein AFF4 and PTEFb, resulting in impaired release of Pol II from promoter-proximal pause sites and a reduced average rate of processive transcription elongation. SEC is required for induction of heat shock genes and treating cells with KL-1 and KL-2 attenuates the heat shock response from Drosophila to human. SEC inhibition downregulates MYC and MYC-dependent transcriptional programs in mammalian cells and delays tumor progression in a mouse xenograft model of MYC-driven cancer, indicating that small molecule disruptors of SEC could be used for targeted therapy of MYC-induced cancer.
converges on the central premise that maximal immunotherapeutic efficacy in subjects with advanced cancer requires both IDO enzyme-and non-enzyme-neutralization, which is not adequately addressed by available IDO-targeting pharmacologic approaches at this time.
Cancer progression and recurrence are linked to a rare population of cancer stem cells (CSC). Here we hypothesized that interactions with the extracellular matrix drive CSC proliferation and tumor-initiating capacity and investigated the functions of scaffold protein tissue transglutaminase (TG2) in ovarian CSC. Complexes formed by TG2, fibronectin (FN), and integrin β1 were enriched in ovarian CSC and detectable in tumors. A function-inhibiting antibody against the TG2 FN-binding domain suppressed complex formation, CSC proliferation as spheroids, tumor-initiating capacity, and stemness-associated Wnt/β-catenin signaling. Disruption of the interaction between TG2 and FN also blocked spheroid formation and the response to Wnt ligands. TG2 and the Wnt receptor Frizzled 7 (Fzd7) form a complex in cancer cells and tumors, leading to Wnt pathway activation. Protein docking and peptide inhibition demonstrate that the interaction between TG2 and Fzd7 overlaps with the FN binding domain of TG2. These results support a new function of TG2 in ovarian CSC, linked to spheroid proliferation and tumor-initiating capacity and mediated through direct interactions with Fzd7. We propose this complex as a new stem cell target.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.